Pharmacoeconomics of asthma treatment

Research output: Contribution to specialist publicationLetter

11 Citations (Scopus)

Abstract

The burden of asthma is increasing in terms of prevalence, severity of symptoms and other markers of asthma control. Poor control of symptoms is a major issue that can result in adverse clinical and economic outcomes. Prescribing costs are the most obvious and visible expense in asthma care but these are but the tip of the iceberg. We need to take all factors into account when considering the overall costs of asthma treatments and recognise that treatment that results in better asthma control may result in lessening of both direct and indirect costs. To assess this accurately, health economic evaluations need to be undertaken in relevant settings, on representative populations. They need to use appropriate measures of asthma outcome. Drug-related costs need to take into account savings made by decreased costs of other prescribed medication and patient factors must be taken into account. We need information that is applicable to the types of patients we see in the real world to make proper cost analyses. Such information can come from 'pragmatic' randomised trials, from retrospective claims analysis from observational studies or using primary care clinical and prescribing databases.

Original languageEnglish
Pages311-318
Number of pages8
Volume4
No.3
Specialist publicationExpert Opinion on Pharmacotherapy
DOIs
Publication statusPublished - 2003

Keywords

  • asthma
  • asthma management
  • pharmacoeconomics
  • quality-of-life
  • cost-effectiveness
  • inhaled corticosteroids
  • respiratory symptoms
  • economic-evaluation
  • childhood asthma
  • self-management
  • United-States
  • New-Zealand
  • children

Cite this

Pharmacoeconomics of asthma treatment. / Cleland, Jennifer Anne; Thomas, Mike; Price, David.

In: Expert Opinion on Pharmacotherapy, Vol. 4, No. 3, 2003, p. 311-318.

Research output: Contribution to specialist publicationLetter

@misc{cdb8dcb708764ec783163ff2e75b2ec7,
title = "Pharmacoeconomics of asthma treatment",
abstract = "The burden of asthma is increasing in terms of prevalence, severity of symptoms and other markers of asthma control. Poor control of symptoms is a major issue that can result in adverse clinical and economic outcomes. Prescribing costs are the most obvious and visible expense in asthma care but these are but the tip of the iceberg. We need to take all factors into account when considering the overall costs of asthma treatments and recognise that treatment that results in better asthma control may result in lessening of both direct and indirect costs. To assess this accurately, health economic evaluations need to be undertaken in relevant settings, on representative populations. They need to use appropriate measures of asthma outcome. Drug-related costs need to take into account savings made by decreased costs of other prescribed medication and patient factors must be taken into account. We need information that is applicable to the types of patients we see in the real world to make proper cost analyses. Such information can come from 'pragmatic' randomised trials, from retrospective claims analysis from observational studies or using primary care clinical and prescribing databases.",
keywords = "asthma, asthma management, pharmacoeconomics, quality-of-life, cost-effectiveness, inhaled corticosteroids, respiratory symptoms, economic-evaluation, childhood asthma , self-management, United-States, New-Zealand, children",
author = "Cleland, {Jennifer Anne} and Mike Thomas and David Price",
year = "2003",
doi = "10.1517/14656566.4.3.311",
language = "English",
volume = "4",
pages = "311--318",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",

}

TY - GEN

T1 - Pharmacoeconomics of asthma treatment

AU - Cleland, Jennifer Anne

AU - Thomas, Mike

AU - Price, David

PY - 2003

Y1 - 2003

N2 - The burden of asthma is increasing in terms of prevalence, severity of symptoms and other markers of asthma control. Poor control of symptoms is a major issue that can result in adverse clinical and economic outcomes. Prescribing costs are the most obvious and visible expense in asthma care but these are but the tip of the iceberg. We need to take all factors into account when considering the overall costs of asthma treatments and recognise that treatment that results in better asthma control may result in lessening of both direct and indirect costs. To assess this accurately, health economic evaluations need to be undertaken in relevant settings, on representative populations. They need to use appropriate measures of asthma outcome. Drug-related costs need to take into account savings made by decreased costs of other prescribed medication and patient factors must be taken into account. We need information that is applicable to the types of patients we see in the real world to make proper cost analyses. Such information can come from 'pragmatic' randomised trials, from retrospective claims analysis from observational studies or using primary care clinical and prescribing databases.

AB - The burden of asthma is increasing in terms of prevalence, severity of symptoms and other markers of asthma control. Poor control of symptoms is a major issue that can result in adverse clinical and economic outcomes. Prescribing costs are the most obvious and visible expense in asthma care but these are but the tip of the iceberg. We need to take all factors into account when considering the overall costs of asthma treatments and recognise that treatment that results in better asthma control may result in lessening of both direct and indirect costs. To assess this accurately, health economic evaluations need to be undertaken in relevant settings, on representative populations. They need to use appropriate measures of asthma outcome. Drug-related costs need to take into account savings made by decreased costs of other prescribed medication and patient factors must be taken into account. We need information that is applicable to the types of patients we see in the real world to make proper cost analyses. Such information can come from 'pragmatic' randomised trials, from retrospective claims analysis from observational studies or using primary care clinical and prescribing databases.

KW - asthma

KW - asthma management

KW - pharmacoeconomics

KW - quality-of-life

KW - cost-effectiveness

KW - inhaled corticosteroids

KW - respiratory symptoms

KW - economic-evaluation

KW - childhood asthma

KW - self-management

KW - United-States

KW - New-Zealand

KW - children

U2 - 10.1517/14656566.4.3.311

DO - 10.1517/14656566.4.3.311

M3 - Letter

VL - 4

SP - 311

EP - 318

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

ER -